Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Operating Cash Flow

Cash generated by the company's core business operations during the period.

Context Therapeutics Inc.NASDAQ: CNTX

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $11.43M (cash outflow) rose 127.3% year over year, ahead of the +115.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 27.8% from the prior quarter. Over 3 fiscal years it compounded at +24.9% a year.

Context

  • Operating cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +127.3% holds above the trailing-twelve-month pace of +115.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.43M+27.8% QoQ
Last fiscal yearDec 2025
-$26.39M+81.3% YoY
LTMMar 2026
-$32.79M+115.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+127.3%——
1 year+81.3%——
3-year CAGR+24.9%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(26.39M) USD
Year-over-year change
-81.3%

Operating Cash Flow vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +115.4% is the 2nd highest of 10, against a peer median of -6.2%.
  • Over three fiscal years its annual growth of +24.9% compares with a peer median of -12.5%.
CNTX Competitors
Operating Cash Flow for CNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WHWKWhitehawk Therapeutics IncLTM Dec 2025$97.43M USD+63.6%+25.2%1363.7%
MGNXMacroGenics, Inc.LTM Mar 2026$69.96M USD+0.5%-2.3%44.5%
IMAImageneBio IncLTM Mar 2026$52.08M USD+36.1%-13.6%—
CNTBConnect Biopharma Holdings LimitedFY2025$51.21M USD+116.9%-19.8%80009.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$48.89M USD—+63.8%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$41.95M USD-15.3%-11.5%589.1%
STTKShattuck Labs, Inc.LTM Mar 2026$41.27M USD-26.8%-25.0%4127.4%
CNTXContext Therapeutics Inc.LTM Mar 2026$32.79M USD+115.4%+24.9%—
IFRXInflaRx N.V.LTM Mar 2026€28.81M EUR-39.6%+0.2%98232.5%
CLNNClene Inc.LTM Mar 2026$18.06M USD-6.2%-22.0%13479.9%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$8.94M USD-14.5%-31.7%—
Peer median (excluding CNTX) —-6.2%-12.5%4127.4%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Depreciation & Amortization09.27K12.04K10.88K16.25K
Deferred Income Tax00000
Stock-Based Compensation511.08K976.44K1.08M841.87K1.33M
Change in Working Capital(2.22M)(277.52K)1.78M(3.48M)6.28M
Accounts Receivables00000
Inventory00000
Accounts Payables(866.01K)(787.89K)1.45M(946K)1.1M
Other Working Capital(1.36M)510.37K329.03K(2.53M)5.19M
Other Non-Cash Items3.37M578.52K51.97K14.79M2.11M
Operating Cash Flow(8.8M)(13.55M)(21.05M)(14.56M)(26.39M)
Capital Expenditures(250K)(536.84K)0(14.76M)(33.95K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities000(14.75M)(2M)
Investing Cash Flow(250K)(536.84K)0(14.76M)(2.03M)
Debt Repayment00000
Common Stock Issued53.41M(102.07K)0109.29M(15.27K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow58.39M(102.07K)0109.29M(15.27K)
Effect of Forex Changes050.39K000
Net Change in Cash49.34M(14.14M)(21.05M)79.98M(28.43M)
Free Cash Flow(9.05M)(14.09M)(21.05M)(29.31M)(26.42M)

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.